Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer's Disease

Ayhan Çetinkaya; Muhammed Emin Demirkol; Ali Osman Avcı

doi:10.18521/ktd.1866798

Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer's Disease

Abstract

Aim: This study aimed to examine whether vortioxetine can improve cognitive performance in a rat model of Alzheimer’s disease induced through intrahippocampal administration of Amyloid-β1–42.

Material and Methods: An experimental Alzheimer’s disease model was generated via stereotaxic bilateral injections of Amyloid-β1–42 into the hippocampus. Twenty-eight rats were randomly assigned to four groups (n=7 each): Group 1 (control) received only saline; Group 2 was administered beta-amyloid to establish the Alzheimer model; Group 3 received beta-amyloid plus donepezil (reference treatment); and Group 4 received beta-amyloid in combination with vortioxetine for 14 days. Cognitive function was assessed using the passive avoidance paradigm. Upon completion of behavioral evaluations, animals were euthanized, and their brains were collected for histopathological examination.

Results: Median latency times in the passive avoidance task were: Group 1, 300 seconds (19.5–300); Group 2, 10.3 seconds (1–300); Group 3, 300 seconds (33.1–300); and Group 4, 300 seconds (8.9–300). Statistical testing revealed a significant difference among groups (p < 0.05). Group 4 exhibited the longest median latency. Groups 1, 3, and 4 showed significantly higher latency scores compared with Group 2. Histopathological findings demonstrated that vortioxetine reduced degenerative changes in hippocampal pyramidal neurons.

Conclusion: This work represents the first experimental study to evaluate vortioxetine’s effects on cognition in an Amyloid-β1–42-induced Alzheimer model. The results suggest that vortioxetine may improve cognitive outcomes and may attenuate neuronal injury

Keywords

Supporting Institution

This study funded by Bolu Abant İzzet Baysal University Scientific Research Projects Board/2018.08.02.1393.

Project Number

2018.08.02.1393

Ethical Statement

The study was conducted in accordance with the approval of Bolu Abant İzzet Baysal University Animal Research Local Ethics Committee (HAYEK), dated February 20, 2020, and numbered 14.

References

Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25(1):59-70. doi:10.1111/ene.13439.
Drummond E, Wisniewski T. Alzheimer's disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155-75. doi:10.1007/s00401-016-1662-x.
Prakash A, Kalra J, Mani V, Ramasamy K, Majeed AB. Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets. Expert Rev Neurother. 2015;15(1):53-71. doi:10.1586/14737175.2015.988709.
Wenzler S, Knochel C, Balaban C, Kraft D, Kopf J, Alves GS, et al. Integrated biomarkers for depression in Alzheimer's disease: a critical review. Curr Alzheimer Res. 2017;14(4):441-52. doi:10.2174/1567205013666160603011256.
Chi S, Wang C, Jiang T, Zhu XC, Yu JT, Tan L. The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. Curr Alzheimer Res. 2015;12(2):189-98. doi:10.2174/1567205012666150204124310.
Lozupone M, La Montagna M, D'Urso F, Piccininni C, Sardone R, Dibello V, et al. Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder. Expert Opin Pharmacother. 2018;19(8):823-42. doi:10.1080/14656566.2018.1471136.
Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673-86. doi:10.1007/s40262-017-0612-7.
Torrisi SA, Geraci F, Tropea MR, Grasso M, Caruso G, Fidilio A, et al. Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by aβ1-42 oligomers in mice: a key role of transforming growth factor-β1. Front Pharmacol. 2019;10:693. doi:10.3389/fphar.2019.00693.

Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment effects of vortioxetine on cognitive functions in mild Alzheimer's disease patients with depressive symptoms: a 12 month, open-label, observational study. J Prev Alzheimers Dis. 2019;6(3):192-197. doi:10.14283/jpad.2019.24.
Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, et al. Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1–42 oligomers are revealed in vivo by using a novel animal model. J Neurosci. 2012;32:7852-61. doi:10.1523/JNEUROSCI.5901-11.2012.
Ambrogi Lorenzini C, Bucherelli C, Giachetti A. Passive and active avoidance behavior in the light-dark box test. Physiol Behav. 1984;32:687-9. doi:10.1016/0031-9384(84)90327-5.
Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2012;1822(5):639-49. doi:10.1016/j.bbadis.2011.10.011.
Soreq H. Checks and balances on cholinergic signaling in brain and body function. Trends Neurosci. 2015;38(7):448-58. doi:10.1016/j.tins.2015.05.007.
Reddy PH. A critical assessment of research on neurotransmitters in Alzheimer's disease. J Alzheimers Dis. 2017;57(4):969-74. doi:10.3233/JAD-170256.
Shaji KS, Sivakumar PT, Rao GP, Paul N. Clinical practice guidelines for management of dementia. Indian J Psychiatry. 2018;60(Suppl 3):S312-28. doi:10.4103/0019-5545.224472.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021;190:108352. doi:10.1016/j.neuropharm.2020.108352.
Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18(6):407-30. doi:10.1016/S0893-133X(97)00194-2.
Starkstein SE, Mizrahi R. Depression in Alzheimer's disease. Expert Rev Neurother. 2006;6(6):887-95. doi:10.1586/14737175.6.6.887.
Caraci F, Spampinato SF, Morgese MG, Tascedda F, Salluzzo MG, Giambirtone MC, et al. Neurobiological links between depression and Alzheimer's disease: the role of TGF-beta1 signaling as a new pharmacological target. Pharmacol Res. 2018;130:374-84. doi:10.1016/j.phrs.2018.02.007.
Chen CP, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol. 2000;26:347-55. doi:10.1046/j.1365-2990.2000.00254.x.
Shen F, Smith JA, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP, et al. 5-HT4 receptor agonist–mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61(1-2):69-79. doi:10.1016/j.neuropharm.2011.02.026.
Fisher JR, Wallace CE, Tripoli DL, Sheline YI, Cirrito JR. Redundant Gs-coupled serotonin receptors regulate amyloid-beta metabolism in vivo. Mol Neurodegener. 2016;11(1):45. doi:10.1186/s13024-016-0112-5.
Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic Alzheimer's disease mice. Sci Transl Med. 2014;6(236):236re4. doi:10.1126/scitranslmed.3008169.
Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136-45. doi:10.1097/JGP.0b013e3181c796eb.
Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403-11. doi:10.1016/S0140-6736(11)60830-1.
Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging. 2012;29:793-806. doi:10.1007/s40266-012-0012-5.
Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58(3):725-33. doi:10.3233/JAD-161247.
Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27:215-23. doi:10.1097/YIC.0b013e3283542457.
Frampton JE. Vortioxetine: a review in cognitive dysfunction in depression. Drugs. 2016;76:1675-82. doi:10.1007/s40265-016-0655-3.
Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014;28(9):855-74. doi:10.1007/s40263-014-0195-x.
Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57. doi:10.1016/j.pharmthera.2014.07.001.
McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-67. doi:10.1017/S1461145714000546.
Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025-37. doi:10.1038/npp.2015.52.
Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, et al. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. Psychopharmacology (Berl). 2019;236(11):3183-95. doi:10.1007/s00213-019-05274-4.

Details

Primary Language

English

Subjects

Health Services and Systems (Other)

Journal Section

Research Article

Authors

Ayhan Çetinkaya ^*
0000-0002-8212-7149
Türkiye

Muhammed Emin Demirkol
0000-0001-6262-6103
Türkiye

Ali Osman Avcı
0000-0002-5849-5988
Türkiye

Publication Date

June 26, 2026

Submission Date

January 20, 2026

Acceptance Date

June 4, 2026

Published in Issue

Year 2026 Volume: 18 Number: 2

DOI

https://doi.org/10.18521/ktd.1866798

IZ

https://izlik.org/JA45TK67GR

Cite

RIS / Bibtex

APA

Çetinkaya, A., Demirkol, M. E., & Avcı, A. O. (2026). Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer’s Disease. Konuralp Medical Journal, 18(2), 110-115. https://doi.org/10.18521/ktd.1866798

AMA

1.Çetinkaya A, Demirkol ME, Avcı AO. Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer’s Disease. Konuralp Medical Journal. 2026;18(2):110-115. doi:10.18521/ktd.1866798

Chicago

Çetinkaya, Ayhan, Muhammed Emin Demirkol, and Ali Osman Avcı. 2026. “Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 Induced Rat Model of Alzheimer’s Disease”. Konuralp Medical Journal 18 (2): 110-15. https://doi.org/10.18521/ktd.1866798.

EndNote

Çetinkaya A, Demirkol ME, Avcı AO (June 1, 2026) Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer’s Disease. Konuralp Medical Journal 18 2 110–115.

IEEE

[1]A. Çetinkaya, M. E. Demirkol, and A. O. Avcı, “Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer’s Disease”, Konuralp Medical Journal, vol. 18, no. 2, pp. 110–115, June 2026, doi: 10.18521/ktd.1866798.

ISNAD

Çetinkaya, Ayhan - Demirkol, Muhammed Emin - Avcı, Ali Osman. “Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 Induced Rat Model of Alzheimer’s Disease”. Konuralp Medical Journal 18/2 (June 1, 2026): 110-115. https://doi.org/10.18521/ktd.1866798.

JAMA

1.Çetinkaya A, Demirkol ME, Avcı AO. Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer’s Disease. Konuralp Medical Journal. 2026;18:110–115.

MLA

Çetinkaya, Ayhan, et al. “Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 Induced Rat Model of Alzheimer’s Disease”. Konuralp Medical Journal, vol. 18, no. 2, June 2026, pp. 110-5, doi:10.18521/ktd.1866798.

Vancouver

1.Ayhan Çetinkaya, Muhammed Emin Demirkol, Ali Osman Avcı. Effect of Vortioxetine on Cognitive Functions in an Amyloid β1–42 induced Rat Model of Alzheimer’s Disease. Konuralp Medical Journal. 2026 Jun. 1;18(2):110-5. doi:10.18521/ktd.1866798